
Labelling government’s thrust on manufacturing sector as mere “lip service”, Biocon chief Kiran Mazumdar-Shaw has said that ease of doing…
The approval will enable the company to address $1.2 billion opportunity, starting FY17 Biocon has received European approvals for its…
Biotechnology major Biocon has reported 13.31 per cent rise in consolidated net profit of Rs 103 crore for the third…
Biocon’s contract research arm Syngene International on Thursday reported 31.25 per cent rise in net profit to Rs 58.8 crore…
Biocon on Thursday announced introduction of an advanced novel therapy for the treatment of Hepatitis C in India – CIMIVIR-L.
Biocon share price gain as much as 1.63 per cent in the early trade after the company informed BSE that…
The BSE Sensex and NSE Nifty are likely to open on a soft-to-cautious note on Thursday tracking SGX Nifty
Biopharmaceuticals firm Biocon is looking to tap opportunities in biosimilars targeting diseases such as diabetes and cancer among others, in…
Biocon share price gained as much as 1.87 per cent in the early trade on Wednesday after the biotechnology major…
Biotechnology major Biocon today reported an over two-fold jump in its consolidated net profit at Rs 306 crore for the…
Mazumdar-Shaw said India has become the pharmacy of the world with its very large presence in the generic space and…
The facility, which is spread over 45,000 square feet, was commissioned in 2008
The company also launches Basalog One, a ready to use insulin glargine disposable pen, for better blood sugar management Biocon…
Highlighting the need for the government to quickly remove bottlenecks to improve ease of doing business, Biocon CMD Kiran Mazumdar-Shaw…
Syngene International, a contract research arm of biotech major Biocon, has firmed up plans to diversify into contract manufacturing.
DLF stocks will be in focus as the company raised Rs 375 crore through non-convertible debentures (NCDs) as a part…